![]() |
市場調查報告書
商品編碼
2088209
獸用寄生蟲防治市場:2026-2032年全球市場預測(依產品類型、目標動物、寄生蟲類型、給藥途徑、通路及最終用戶分類)Animal Parasiticides Market by Product Type, Animal Type, Parasite Type, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,動物寄生蟲防治市場將成長至 297.8 億美元,複合年成長率為 10.06%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 152.2億美元 |
| 預計年份:2026年 | 164.6億美元 |
| 預測年份 2032 | 297.8億美元 |
| 複合年成長率 (%) | 10.06% |
獸用寄生蟲防治劑是用於預防、治療和控制伴侶動物和肉類用牲畜體內外寄生蟲的重要動物用藥品。該市場包括內源性驅蟲藥,可控制跳蚤、蜱蟲、蟎蟲、蝨子、心絲蟲、胃腸道寄生蟲以及其他多種寄生蟲,其劑型包括口服、外用、注射、塗抹、噴霧、項圈和飼料添加劑等。
需求成長的促進因素包括寵物飼養量的增加、對高階伴侶動物照護需求的優質化、畜牧業生產力提高的需求以及人們對通用感染疾病風險認知的提高。美國食品藥物管理局獸醫中心、歐洲藥品管理局 (EMA) 和各國獸醫機構等監管機構的監管,持續影響人們對產品功效標籤、安全要求、殘留限量、停藥期和環境控制等方面的預期。
對於動物保健行業的製造商、經銷商、獸醫、畜牧養殖戶和投資者而言,永續成長取決於在有效性、便利性、抗藥性管理、可負擔性以及遵守不斷變化的有關殘留物、正確使用抗寄生蟲藥物、藥物安全監測和環境暴露的法規之間取得平衡。
獸醫寄生蟲防治領域正從被動的寄生蟲治療轉向全年預防、基於風險的用藥和綜合寄生蟲管理。寵物飼主越來越傾向選擇便利的每月用藥和長效產品,而畜牧養殖戶則優先考慮能夠保障生產力、動物福利和食品安全的群體層面防治方案。
人工智慧(AI)正對獸用寄生蟲控制劑的研發、商業化和合理使用等各領域產生累積影響。在藥物發現和製劑開發階段,人工智慧驅動的分子篩檢、預測毒理學和藥物動力學建模能夠對候選化合物進行優先排序,最佳化劑型開發,並在進行成本高的田間試驗之前識別潛在的安全隱患。
亞太地區因其大規模的畜牧業基礎、不斷擴張的水產養殖和家禽業以及都市區市場中寵物飼養量的增加,成為重點區域。中國、印度、日本、韓國、澳洲和東南亞國協的需求模式多樣,涵蓋了從經濟實惠的牲畜驅蟲和體外寄生蟲控制產品到高階寵物跳蚤、蜱蟲和心絲蟲預防產品。儘管該地區部分地區普遍存在的熱帶和亞熱帶氣候加劇了寄生蟲的威脅,但日本、韓國和澳洲等已開發市場更加重視安全性、合規性和獸醫主導的預防性護理。
隨著畜牧業集約化發展、寵物飼養規模擴大以及東南亞地區獸醫零售網路的擴張,東協市場的重要性日益凸顯。該地區的熱帶氣候意味著寄生蟲威脅全年持續存在,因此有效控制跳蚤、蜱蟲、蟎蟲和線蟲對於伴侶動物和生產動物至關重要。此外,獸醫服務可及性和購買力方面的差異也凸顯了價格合理的藥品配方、經銷商的品質以及使用者教育的重要性。
在獸醫推薦、預防心絲蟲、跳蚤和蜱蟲控制、零售通路的便利性以及人們對寵物保健的高度重視等因素的推動下,美國已成為全球伴侶動物驅蟲產品的標竿市場。加拿大也有類似的預防保健措施,季節性和區域性寄生蟲風險會影響產品的選擇。同時,墨西哥正面臨伴侶動物照護和牲畜寄生蟲控制需求雙雙成長的局面。巴西擁有大規模的畜牧業基礎和完善的獸藥分銷網路,是牛驅蟲藥、蜱蟲控制藥、內分泌干擾物以及快速成長的寵物護理行業的主要需求中心。
產業領導者應優先研發差異化的抗寄生蟲產品,這些產品不僅療效顯著,而且兼具便利性、安全性和遵守用藥優勢。投資研發長效製劑、頻譜複方製劑、偏好良好的劑型、精準的劑量控制以及針對特定物種的給藥方法,有助於提高客戶留存率和獸醫信心。
本執行摘要基於系統性的研究途徑,結合了二手資料調查、證據三角檢驗和專家解讀。在分析獸用寄生蟲控制劑時,通常引用的資訊來源包括獸醫監管機構、產品標籤、藥物警戒指南、動物健康協會、同行評審的寄生蟲學文獻、牲畜和寵物數量指標、疾病監測出版物以及可獲得的行業數據。
隨著寵物飼主、獸醫、畜牧生產者和公共衛生利益相關人員日益關注寄生蟲預防、動物福利、食品安全以及降低通用感染疾病風險,獸用寄生蟲防治市場預計將保持其重要的戰略地位。能夠提供可靠療效、便捷給藥方式、負責任的管理以及在地化推廣策略的機構,將獲得最強勁的發展動能。
The Animal Parasiticides Market is projected to grow by USD 29.78 billion at a CAGR of 10.06% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 15.22 billion |
| Estimated Year [2026] | USD 16.46 billion |
| Forecast Year [2032] | USD 29.78 billion |
| CAGR (%) | 10.06% |
Animal parasiticides are essential veterinary pharmaceuticals used to prevent, treat, and control ectoparasites and endoparasites in companion animals and food-producing livestock. The market spans flea, tick, mite, lice, heartworm, gastrointestinal worm, and broad-spectrum endectocide solutions delivered through oral, topical, injectable, pour-on, spray, collar, and feed-additive formats.
Demand is supported by rising pet ownership, premiumization of companion animal care, livestock productivity requirements, and increasing awareness of zoonotic disease risks. Regulatory oversight from agencies such as the U.S. FDA Center for Veterinary Medicine, the European Medicines Agency, and national veterinary authorities continues to shape product claims, safety requirements, residue limits, withdrawal periods, and environmental stewardship expectations.
For manufacturers, distributors, veterinarians, livestock producers, and animal health investors, sustainable growth depends on balancing efficacy, convenience, resistance management, affordability, and compliance with evolving rules on residues, antiparasitic stewardship, pharmacovigilance, and environmental exposure.
The animal parasiticides landscape is shifting from reactive parasite treatment toward year-round prevention, risk-based dosing, and integrated parasite management. Companion animal owners increasingly favor convenient monthly or longer-duration products, while livestock producers prioritize herd-level protocols that protect productivity, animal welfare, and food safety.
Product portfolios are also evolving. Broad-spectrum combinations, palatable oral formulations, long-acting injectables, pour-on treatments, collars, and species-specific delivery systems are gaining strategic importance as veterinarians and producers seek dependable compliance. At the same time, documented parasite resistance to established drug classes is driving demand for diagnostic surveillance, rotation strategies, refugia-based approaches, and new modes of action.
Digital commerce, veterinary telehealth, and direct-to-consumer education are changing how pet owners discover and purchase parasite prevention products. However, prescription controls, counterfeit-product risk, label-compliance requirements, and the need for veterinary guidance keep professional channels central to responsible parasiticide use.
Artificial intelligence is becoming a cumulative force across animal parasiticide research, commercialization, and stewardship. In discovery and formulation, AI-enabled molecular screening, predictive toxicology, and pharmacokinetic modeling can help prioritize candidates, refine dose-form development, and identify potential safety concerns before costly field studies.
In the field, AI can strengthen parasite surveillance by combining veterinary clinic records, diagnostic results, climate data, geospatial signals, livestock movement patterns, and farm-management information to anticipate seasonal parasite pressure. This supports targeted treatment recommendations and helps reduce unnecessary exposure that may accelerate resistance.
AI also improves commercial execution through demand-planning analytics, pharmacovigilance signal detection, supply-chain risk monitoring, and personalized customer education. The greatest value will come from governed systems that protect data privacy, preserve veterinarian oversight, document model limitations, and align algorithmic recommendations with approved product labels and local regulations.
Asia-Pacific is a high-priority region due to its large livestock base, expanding aquaculture and poultry sectors, and rising companion animal adoption in urban markets. China, India, Japan, South Korea, Australia, and ASEAN countries show different demand patterns, ranging from cost-effective livestock dewormers and ectoparasiticides to premium flea, tick, and heartworm prevention products for pets. Tropical and subtropical climates across parts of the region support persistent parasite pressure, while developed markets such as Japan, South Korea, and Australia place greater emphasis on safety, compliance, and veterinary-led preventive care.
North America remains one of the most mature regions, supported by high veterinary service utilization, advanced companion animal care, broad retail and clinic channels, and established regulatory oversight. The United States and Canada emphasize year-round parasite prevention for dogs and cats, including heartworm, flea, and tick control, while food-animal demand is influenced by productivity, residue compliance, withdrawal-period adherence, and veterinary supervision. Latin America is shaped by large cattle and companion animal populations, with Brazil and Mexico playing central roles in demand for tick control, gastrointestinal worm management, ectoparasiticides, endoparasiticides, and endectocides.
Europe is driven by stringent regulatory standards, pharmacovigilance, residue monitoring, and sustainability expectations, particularly within the European Union, where veterinary medicinal product rules and environmental risk assessment shape market access. The Middle East is supported by premium companion animal care, equine and camel health requirements, and livestock health programs in GCC markets. Africa presents long-term opportunity tied to livestock disease control, food security, smallholder productivity, and access to affordable, quality-assured veterinary medicines, with parasite control remaining important across cattle, sheep, goats, poultry, and companion animals.
ASEAN markets are gaining relevance as livestock intensification, pet ownership, and veterinary retail networks expand across Southeast Asia. The region's tropical climate sustains year-round parasite pressure, making effective flea, tick, mite, and helminth control important for companion animals and production animals. Variability in veterinary access and purchasing power also increases the importance of affordable formulations, distributor quality, and user education.
The GCC is characterized by high-income urban pet care, equine and camel health requirements, and growing interest in premium veterinary services, with demand shaped by climate-related parasite exposure, import dependence, and high expectations for product authenticity. In the European Union, harmonized veterinary medicinal product rules, environmental risk assessment, residue controls, and pharmacovigilance make regulatory compliance a core competitive factor for parasiticide suppliers.
BRICS countries represent large-volume relevance because of major livestock populations, fast-growing pet care markets, and increasing domestic animal health manufacturing capacity. G7 markets are typically innovation-led, with strong demand for branded companion animal parasiticides, advanced veterinary diagnostics, and label-driven preventive care. NATO member economies overlap significantly with established regulatory systems and high standards for supply security, pharmacovigilance, veterinary infrastructure, and resilience of essential animal health products.
The United States is a global reference market for companion animal parasiticides, driven by veterinary recommendation, heartworm prevention, flea and tick control, retail availability, and high pet healthcare engagement. Canada shows similar preventive-care behavior, with seasonal and regional parasite risk influencing product selection, while Mexico combines expanding companion animal care with livestock parasite control needs. Brazil is a major demand center for cattle parasiticides, tick control, endectocides, and a growing pet care segment, supported by its large livestock base and strong veterinary distribution networks.
In Europe, the United Kingdom, Germany, France, Italy, and Spain are supported by developed veterinary networks, premium pet ownership, and strict product safety standards. Germany and France emphasize regulated veterinary medicine use and quality assurance, while Italy and Spain combine companion animal demand with livestock parasite management needs in diverse production systems. Russia remains relevant due to livestock scale and companion animal demand, although trade, regulatory, and supply-chain conditions influence market access and product availability.
China and India offer significant long-term potential because of large animal populations, rising protein demand, expanding pet ownership, and growing attention to animal disease prevention. China's companion animal sector is increasingly urban and premium-oriented, while India's demand is supported by dairy, small ruminants, poultry, and companion animal healthcare. Japan and South Korea are premium companion animal markets with strong expectations for safety, convenience, and veterinary guidance. Australia's livestock and companion animal sectors require robust parasite management due to diverse climate zones, biosecurity priorities, tick and helminth pressure, and well-established veterinary practices.
Industry leaders should prioritize differentiated parasiticide products that combine proven efficacy with convenience, safety, and adherence benefits. Investments in long-acting formulations, broad-spectrum combinations, palatable delivery, precision dosing, and species-specific administration can improve customer retention and veterinarian confidence.
Companies should strengthen resistance-management programs by supporting diagnostic testing, parasite surveillance, rotation guidance, refugia-based education, and responsible-use training. Clear stewardship messaging is increasingly important as regulators, veterinarians, producers, and pet owners scrutinize environmental exposure, residue compliance, and unnecessary dosing.
Commercial teams should align channel strategy with local regulations and customer behavior. In mature markets, veterinary endorsement, digital education, subscription models, label-compliant communication, and pharmacovigilance excellence are critical. In emerging markets, affordability, cold-chain resilience where relevant, distributor quality, anti-counterfeit measures, and training for veterinary professionals can unlock sustainable growth.
This executive summary is built from a structured research approach combining secondary research, evidence triangulation, and expert interpretation. Sources typically reviewed for animal parasiticide analysis include veterinary regulatory agencies, product labels, pharmacovigilance guidance, animal health associations, peer-reviewed parasitology literature, livestock and pet population indicators, disease surveillance publications, and trade data where available.
The methodology evaluates the market by animal type, parasite type, product class, route of administration, distribution channel, regulatory environment, and geography. Demand signals are cross-checked against regulatory approvals, disease prevalence patterns, veterinary practice trends, livestock production systems, companion animal spending behavior, climate-linked parasite risk, and public animal health priorities.
Insights are validated through consistency checks across public datasets, clinical and field-use evidence, regional policy developments, and documented veterinary practice patterns. AI-assisted synthesis may support pattern recognition and terminology standardization, but final interpretation requires human review to ensure accuracy, relevance, and compliance with verified market evidence.
The animal parasiticides market is positioned for continued strategic importance as pet owners, veterinarians, livestock producers, and public health stakeholders intensify focus on parasite prevention, animal welfare, food security, and zoonotic disease risk reduction. Momentum will be strongest for organizations that deliver reliable efficacy, convenient administration, responsible stewardship, and region-specific access strategies.
Artificial intelligence, improved diagnostics, climate-informed surveillance, and targeted treatment models will help reshape competition, but regulatory compliance and veterinarian trust will remain decisive. Organizations that pair innovation with education, pharmacovigilance, quality assurance, and sustainability will be best placed to create long-term value in the global animal parasiticides industry.